FIELD: biotechnology.
SUBSTANCE: disclosed are isolated monoclonal antibodies which specifically bind human Siglec15, or antigen-binding portions thereof, and use thereof. Also disclosed is a polynucleotide encoding a heavy chain variable region and a light chain variable region of an antibody, a pharmaceutical composition comprising the antibody or an antigen-binding portion thereof, as well as a method of treating cancer and a method of inhibiting bone loss in a subject.
EFFECT: invention can be used to treat cancer in a subject.
21 cl, 6 tbl, 22 dwg, 14 ex
| Title | Year | Author | Number |
|---|---|---|---|
| CYTOTOXICITY-INDUCING THERAPEUTIC AGENT | 2015 |
|
RU2743464C2 |
| TUMOR-TARGETING AGONIST CD28 ANTIGEN-BINDING MOLECULES | 2019 |
|
RU2837821C1 |
| TUMOR-TARGETED AGONISTIC CD28-ANTIGEN-BINDING MOLECULES | 2019 |
|
RU2808030C2 |
| ANTI-PCSK9 ANTIBODY, ITS ANTIGEN-BINDING DOMAIN AND MEDICAL APPLICATION THEREOF | 2016 |
|
RU2739208C2 |
| BISPECIFIC PROTEIN | 2019 |
|
RU2784486C1 |
| PROCOAGULANT ANTIBODIES | 2018 |
|
RU2810094C2 |
| CD40 LIGAND THERAPEUTIC ANTIBODIES | 2018 |
|
RU2770209C2 |
| AMATOXIN ANTIBODY-DRUG CONJUGATES AND USE THEREOF | 2020 |
|
RU2826004C2 |
| ANTI-LILRB1 ANTIBODY AND USES THEREOF | 2021 |
|
RU2813373C1 |
| MULTIVALENT Fv-ANTIBODIES | 2016 |
|
RU2785766C2 |
